|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Collegium Pharmaceutical, Inc (COLL) |
|
|
$38.78 0.00 (0.00%) as of 4:30 Wed 9/18
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.61(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.16 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 572 |
Guru Rank Value : 3.2 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
29,818 |
211,529 |
344,809 |
1,040,089 |
Total Sell Value |
$1,125,112 |
$7,212,519 |
$11,241,366 |
$27,146,842 |
Total People Sold |
2 |
5 |
6 |
7 |
Total Sell Transactions |
3 |
8 |
16 |
45 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Smith Thomas B |
EVP and Chief Medical Officer |
|
2024-02-29 |
4 |
S |
$36.76 |
$36,580 |
D/D |
(995) |
63,409 |
|
13% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-02-26 |
4 |
AS |
$36.38 |
$364,270 |
D/D |
(10,000) |
138,918 |
|
-13% |
|
Smith Thomas B |
EVP and Chief Medical Officer |
|
2024-02-12 |
4 |
D |
$33.70 |
$107,806 |
D/D |
(3,199) |
64,404 |
|
- |
|
Smith Thomas B |
EVP and Chief Medical Officer |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
35,423 |
67,603 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2024-02-12 |
4 |
D |
$33.70 |
$4,342,818 |
D/D |
(128,867) |
444,867 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
298,734 |
573,734 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-02-12 |
4 |
D |
$33.70 |
$1,000,553 |
D/D |
(29,690) |
148,918 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
67,286 |
178,608 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2024-02-12 |
4 |
D |
$33.70 |
$1,070,177 |
D/D |
(31,756) |
164,409 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
76,647 |
196,165 |
|
- |
|
Tupper Colleen |
EVP & Chief Financial Officer |
|
2024-02-12 |
4 |
D |
$33.70 |
$887,018 |
D/D |
(26,321) |
150,555 |
|
- |
|
Tupper Colleen |
EVP & Chief Financial Officer |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
71,456 |
176,876 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-01-16 |
4 |
AS |
$32.28 |
$760,519 |
D/D |
(23,560) |
111,322 |
|
6% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-21 |
4 |
AS |
$30.38 |
$132,377 |
D/D |
(4,357) |
275,000 |
|
23% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-21 |
4 |
OE |
$21.34 |
$92,978 |
D/D |
4,357 |
279,357 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-20 |
4 |
AS |
$30.40 |
$804,210 |
D/D |
(26,454) |
275,000 |
|
26% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-20 |
4 |
OE |
$21.34 |
$564,528 |
D/D |
26,454 |
301,454 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-19 |
4 |
AS |
$30.03 |
$435,942 |
D/D |
(14,516) |
275,000 |
|
26% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-19 |
4 |
OE |
$21.34 |
$309,771 |
D/D |
14,516 |
289,516 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-18 |
4 |
AS |
$30.04 |
$834,935 |
D/D |
(27,798) |
275,000 |
|
23% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-12-18 |
4 |
OE |
$21.34 |
$593,209 |
D/D |
27,798 |
302,798 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2023-11-27 |
4 |
AS |
$25.78 |
$660,014 |
D/D |
(25,600) |
119,518 |
|
52% |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2023-11-27 |
4 |
OE |
$15.90 |
$407,040 |
D/D |
25,600 |
145,118 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2023-06-26 |
4 |
AS |
$21.65 |
$390,633 |
D/D |
(17,984) |
119,518 |
|
2% |
|
Ciaffoni Joseph |
President and CEO |
|
2023-06-02 |
4 |
AS |
$21.58 |
$675,424 |
D/D |
(31,272) |
275,000 |
|
8% |
|
391 Records found
|
|
Page 1 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|